Advancing Confident Diagnosis and Early Prediction for Preeclampsia
Diagnostic Performance
Validated
Predictive Performance
To-be-validated
A blood draw quantifies biomarker proteins on circulating vascular cells — confirming preeclampsia after symptoms appear and predicting it before.
Patent-Pending Technology
Our test uses a single, clinically actionable cutoff and delivers strong diagnostic performance across a broad, inclusive pregnancy population—including individuals without traditional risk factors and those with chronic hypertension, diabetes, IVF conception, multiple gestation, obesity, or maternal age of 35 years or older.
Sensitivity
79%
Specificity
62%
AUC
0.79
Single Clear Readout
Provides one straightforward result using a single validated cutoff value.
Inclusive Cohort
Validated across both uncomplicated and high-risk pregnancies, including chronic hypertension, diabetes, IVF, twins, obesity, and maternal age 35 or older.
Simple Implementation
Requires a standard 6–10 mL blood draw, under 4 hours of processing time, and only routine clinical laboratory equipment.
Test Performance Data
(coming soon)
- Diagnostic Performance
- Predictive Performance
- Learn more
Backed by several non-dilutive grant funding
National Science Foundation (NSF), National Institute of Health (NIH), Institution of Translational Health Sciences (ITHS) at the University of Washington (UW), We-REACH at UW, and CoMotion at UW.
